Gritstone bio, Inc. (GRTSQ)

OTCMKTS · Delayed Price · Currency is USD
0.0131
+0.0031 (31.00%)
Dec 26, 2024, 4:00 PM EST
-99.28%
Market Cap 1.55M
Revenue (ttm) 14.61M
Net Income (ttm) -133.03M
Shares Out 118.11M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 773,165
Open 0.0140
Previous Close 0.0100
Day's Range 0.0130 - 0.0150
52-Week Range 0.0100 - 3.1700
Beta 0.50
Analysts n/a
Price Target n/a
Earnings Date Mar 6, 2025

About Gritstone bio

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatme... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 231
Stock Exchange OTCMKTS
Ticker Symbol GRTSQ
Full Company Profile

Financial Performance

In 2023, Gritstone bio's revenue was $16.34 million, a decrease of -18.05% compared to the previous year's $19.95 million. Losses were -$138.49 million, 15.7% more than in 2022.

Financial Statements

News

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update

-- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with ...

6 weeks ago - GlobeNewsWire

Bankrupt Gritstone bio in funding talks

Gritstone Bio, which filed for Chapter 11 bankruptcy, is in talks for funding to keep the company running. Read more here.

2 months ago - Seeking Alpha

Covid-Shot Maker Goes Bankrupt After Trailing Pfizer, Moderna

Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday.

2 months ago - BNN Bloomberg

Gritstone bio files for Chapter 11 bankruptcy protection, shares tumble

Gritstone Bio files for Chapter 11 bankruptcy, aims to preserve value and continue with clinical programs despite stock plummeting 90% YTD.

2 months ago - Seeking Alpha

Gritstone downgraded by Jones, B. Riley over cancer vaccine data

Gritstone bio (GRTS) was downgraded by Jones Research and B. Riley on Wednesday, the day after the stock cratered on mixed data for its GRANITE cancer vaccine. Read more here.

3 months ago - Seeking Alpha

Penny Stock Gritstone Bio Hires Advisor To Evaluate Options, Analyst Downgrades Stock As Data 'Insufficient To Excite Many Investors'

On Monday, Gritstone Bio Inc. (NASDAQ: GRTS) revealed interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline micro...

3 months ago - Benzinga

Gritstone falls amid Phase 2 Granite data, corporate update

Gritstone (GRTS) stock fell 10% post-market Monday after the company announced Phase 2 data and that it had retained a financial advisor to review potential strategies.

3 months ago - Seeking Alpha